Cohance Lifesciences
K. Nagendra Babu serves as the Group Chief Quality and Compliance Officer for Suven Pharmaceuticals and Cohance Lifesciences, overseeing quality operations and regulatory affairs across various sectors, including CDMO, API, PFI, FDF, and CRO. With a substantial background in quality assurance and compliance, K. Nagendra Babu has successfully integrated multiple newly acquired businesses, ensuring synergies and business continuity. Previous roles include senior leadership positions at Mylan, Graviti Pharmaceuticals, and Granules India Limited, focusing on quality systems, global audit, compliance, and vendor management. K. Nagendra Babu holds a Ph.D. in Chemistry from Annamalai University and has a strong foundation in chemistry and mathematics from prior academic achievements.
Cohance Lifesciences
Cohance Lifesciences is a global, merchant API platform. With 8 manufacturing units (including 5 USFDA approved units) and 2 R&D dedicated units, we serve our marquee clients as partner of choice in a range of niche Intermediates, API, Pharmaceutical Formulation intermediates (PFI), Formulations & Speciality chemicals across both Innovator and Generic molecules. We also specialise in highly specialised CRAMS and Clinical research. As a global player, we have presence in 60 countries and have a growing product basket of 80+ molecules backed by robust R&D and Infrastructure.